Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31266381 | 0.81 | MAPT (0.45) | MAPTALOX15ELANESIRT2SMN1; SMN2 | |
| SCHEMBL5847420 | 0.80 | MAPT (0.46) | MAPTALOX15ELANESIRT2SMN1; SMN2 | |
| SCHEMBL2799525 | 0.79 | TLR8 (0.39) | MAPTALOX15ELANESIRT2SMN1; SMN2 | |
| SCHEMBL12285604 | 0.77 | ELANE (0.51) | MAPTALOX15ELANESIRT2SMN1; SMN2 | |
| SCHEMBL2782253 | 0.75 | MAPT (0.53) | MAPTALOX15ELANESIRT2SMN1; SMN2 | |
| SCHEMBL10828996 | 0.72 | MAPT (0.47) | MAPTALOX15ELANESIRT2SMN1; SMN2 | |
| SCHEMBL7079565 | 0.71 | ELANE (0.59) | MAPTALOX15ELANESIRT2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7081099 | 0.70 | ELANE (0.58) | MAPTALOX15ELANESIRT2SMN1; SMN2 | |
| SCHEMBL3600551 | 0.69 | PRKDC (0.47) | — | |
| SCHEMBL6237632 | 0.69 | MAPT (0.82) | MAPTALOX15ELANESIRT2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485377-B9 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| EP-2174939-A1 | Pyranones useful as ATM inhibitors | Kudos Pharmaceuticals Limited (GB) | 2010-04-14 | — | — | EP | disclosed |
| EP-1654257-B1 | AMINOPYRONES AND THEIR USE AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-7642254-B2 | ATM inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| EP-1485377-B1 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-20090043091-A1 | Induce immunology response; anticancer agents; 6-(6-Morpholin-4-yl-4-oxo-4H-pyran-2-yl)-thianthrene-2-carboxylate sodium salt; 6-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-thianthrene-2-carboxylic acid methyl ester | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7429660-B2 | ATM inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1848712-A1 | ATM INHIBITORS | Kudos Pharmaceuticals Ltd (GB) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006085067-A1 | ATM INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-17 | — | — | WO | disclosed |
| US-20060178361-A1 | ATM inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-10 | — | — | US | disclosed |
| US-7049313-B2 | ATM inhibitors | KUDOS PHARMACEUTICALS LTD. (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1654257-A1 | AMINOPYRONES AND THEIR USE AS ATM INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2006-05-10 | — | — | EP | disclosed |
| US-20050054657-A1 | ATM inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-03-10 | — | — | US | disclosed |
| WO-2005016919-A1 | AMINOPYRONES AND THEIR USE AS ATM INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| EP-1485377-A1 | PYRANONES USEFUL AS ATM INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2004-12-15 | — | — | EP | disclosed |
| US-20040002492-A1 | Induce immunology response; anticancer agents | KUDOS PHARMACEUTICALS LTD (GB) | 2004-01-01 | — | — | US | disclosed |
| WO-2003070726-A1 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARMACEUTICALS LTD (GB) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002492-A1 | Induce immunology response; anticancer agents | MYD88, IFNG, HCCS | MAPT 4832/4885ALOX15 1214/4885ELANE 4246/4885 |
| US-20060178361-A1 | ATM inhibitors | ATM, CHEK2, ATR | MAPT 1466/4885ALOX15 4526/4885ELANE 2809/4885 |
| US-20090043091-A1 | Induce immunology response; anticancer agents; 6-(6-Morpholin-4-yl-4-oxo-4H-pyran-2-yl)-thianthrene-2-carboxylate sodium salt; 6-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-thianthrene-2-carboxylic acid methyl ester | MYD88, MCL1, TLR1 | MAPT 4311/4885ALOX15 602/4885ELANE 1459/4885 |
| US-20050054657-A1 | ATM inhibitors | ATM, ATR, CHEK2 | MAPT 1236/4885ALOX15 3998/4885ELANE 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.